Latest:
Dr. Muss on the Use of Metronomic Chemotherapy in Metastatic Breast Cancer
Hyman B. Muss, MD, discusses the use of metronomic chemotherapy in metastatic breast cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Hyung L. Kim, MD
Latest:
Dr. Kim on Combining Immunotherapy and TKIs in Metastatic RCC
Hyung L. Kim, MD, Medallion Group Chair in Urology, co-medical director of the Urologic Oncology Center, associate director, Surgical Research in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses the potential combination of immunotherapy and tyrosine kinase inhibitors in metastatic renal cell carcinoma.
Ian Chau, MD
Latest:
Dr. Chau on Nivolumab in Asian Versus Western Patients With Gastric/GEJ Cancer
Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the findings of an analysis of nivolumab (Opdivo) in Asian versus Western patients with gastric/gastroesophageal junction (GEJ) cancer.
Ian Davis, MBBS, PhD, FRACP, FAChPM
Latest:
Dr. Davis on the ANZUP Collaboration on the ENZAMET Trial in Prostate Cancer
Ian Davis, MBBS, PhD, FRACP, FAChPM, professor of medicine at Monash University and Eastern Health, and head of the Eastern Health Clinical School, discusses the Australian and New Zealand Urogenital and Prostate Cancer Trials Group collaboration on the randomizedphase III ENZAMET trial in metastatic hormone-sensitive prostate cancer.
Ian Flinn, MD
Latest:
Dr. Flinn on the FDA Approval of Duvelisib in CLL and Follicular Lymphoma
Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of duvelisib (Copiktra) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.
Ian Flinn, MD, PhD, Sarah Cannon Research Institute
Latest:
Case Discussion: 68-Year-Old With R/R Follicular Lymphoma
A panel of hematologist-oncologists share best practices for managing a 68-year-old male with relapsed/refractory follicular lymphoma who is under consideration for treatment with tazemetostat.
Ian M. Thompson, MD
Latest:
Dr. Thompson on Prostate Biopsy Problems and Solutions
Ian M. Thompson, MD, director, professor, Department of Urology, Cancer Therapy & Research Center, The University of Texas Health Science Center, discusses the problems with prostate biopsies and some possible solutions.
Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute
Latest:
Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in Care
Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.